Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products
Stocks in this Quantisnow insightHealth Care
Quantisnow market dataNASDAQ
KMDA
Kamada Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2013
Get push alerts for KMDA
Full KMDA profile on Quantisnow Follow KMDA and get a push notification the moment its next story breaks.